USD/JPY: Testing overnight highs after BOJ comments

Organon jumps on $12B bid news, reversing 40% annual loss. Sun Pharma eyes acquisition.

Micron's P/E of 6 could hit 15-20 on inference & edge AI, projecting a 10x market cap jump.

Kadant's 18.7% return is strong, but declining EPS & ROIC signal risk. At 27.4x P/E, it's pricey.

DraftKings stock down 31.9% on slowing growth & negative margins. Trades at 23.5x P/E, signaling optimism priced in.

Fusion startups raise billions, targeting trillion-dollar energy markets. Risks remain high, but tech advances fuel optimism.

Buyer's markets surge in former hot spots as inventory grows & price cuts loom. Sellers still hold sway in tight markets.

HY's 6% revenue growth & break-even FCF raise flags. Debt-heavy, it trades at 18.3x EV/EBITDA.